Life Sciences

  • August 03, 2026

    7th Circ. Backs OB-GYN's 10-Year Healthcare Fraud Sentence

    The Seventh Circuit has upheld a 10-year prison sentence for a former obstetrician-gynecologist over a multimillion-dollar healthcare fraud scheme, saying the district judge made no clear error in applying an enhancement to her sentence for performing invasive and medically unnecessary procedures on patients without their informed consent.

  • August 03, 2026

    Novo False-Ad Claims Against Telehealth Co. Fail, For Now

    A New York federal court tossed a false advertising suit by Novo Nordisk against a telehealth company that markets compounded weight loss medications, finding the pharmaceutical giant failed to point to literal or implied false statements made by the company.

  • August 03, 2026

    4 Firms Steer Curium's $8B Lantheus Take-Private Deal

    Private equity-backed radiopharmaceutical company Curium on Monday announced plans to acquire fellow radiopharmaceutical company Lantheus Holdings Inc. in an $8 billion take-private deal built by four law firms.

  • August 03, 2026

    Sandoz Settles States' Generics Price-Fixing Cases For $450M

    Sandoz reached a settlement with a coalition of state enforcers on Monday, agreeing to pay $450 million to end claims against it in several cases targeting alleged price-fixing in the generic-drug industry.

  • August 03, 2026

    Baker Botts Hires Litigators In DC And London

    Baker Botts LLP has hired two litigators who focus on representing companies in highly regulated and technically sophisticated industries as partners in its offices in Washington, D.C., and London, the firm announced Monday.

  • August 03, 2026

    Pfizer COVID Vaccine Suit Needs 3-Judge Court, Panel Finds

    The D.C. Circuit has revived a couple's suit against Pfizer Inc., federal officials and a pediatrician's office alleging their child died after receiving the COVID-19 vaccine, saying federal law required a three-judge court to decide motions to dismiss, not the single judge who tossed the case.

  • August 03, 2026

    KKR Buying Integer For $5.7B In Kirkland, Davis Polk-Led Deal

    KKR said Monday that it will acquire medical device company Integer Holdings Corp. in an all-cash transaction with a roughly $5.7 billion enterprise value, with Kirkland & Ellis LLP and Davis Polk & Wardwell LLP advising on the transaction. 

  • August 03, 2026

    Bath Product Maker Vi-Jon Hits Ch. 11 With $25M Talc Deal

    Private-label dry bath product maker Vi-Jon LLC filed for Chapter 11 protection in Delaware with a proposed plan to channel talc injury claims into a trust to be funded by $25 million of cash and the contribution of certain insurance rights.

  • August 03, 2026

    Former Gates Foundation Deputy GC Joins Arnold & Porter

    The former deputy counsel of the Gates Foundation has joined Arnold & Porter Kaye Scholer LLP's life sciences and technology transactions teams in the corporate and finance practice, the firm announced Monday.

  • July 31, 2026

    Law360 Names 2026's Top Attorneys Under 40

    Law360 is pleased to announce the Rising Stars of 2026, our list of more than 160 attorneys under 40 whose legal accomplishments belie their age.

  • July 31, 2026

    Mich. Justices' Ruling Will Allow Eli Lilly Price-Fixing Probe

    A split Michigan Supreme Court Friday overturned two of its prior rulings that the majority determined had wrongly expanded an exemption in the Michigan Consumer Protection Act, opening the door for the state's attorney general to take action against misconduct in a range of industry sectors.

  • July 31, 2026

    Appeals Courts Upheld Similar E-Cig Regs, Pa. Tells Court

    There's no good reason to block Pennsylvania from enforcing a statewide ban on most vape products, the commonwealth has told a Pennsylvania federal court, saying many appeals courts across the country have come to the same conclusion that such laws are constitutional.

  • July 31, 2026

    Lab, Ex-CEO, Fla. Resident To Pay $36M Over Kickback Claims

    A Texas-based laboratory, its former CEO and a Florida businessman have each entered into settlements with the U.S. government totaling $36.4 million to resolve claims they paid kickbacks and billed Medicare and Medicaid for unnecessary medical genetic testing, in violation of the False Claims Act.

  • July 31, 2026

    Fed. Circ. Says Leica's Filtered Light Skirts U. Mich. Patent

    In a dispute centered on how laser light is used in fluorescence technology, a unanimous Federal Circuit panel said on Friday that Leica Microsystems did not infringe on a University of Michigan patent, affirming the decision of a federal court in California.

  • July 31, 2026

    TRESemme Hair Loss Suit Filed 2 Years Too Late, Judge Finds

    A New York federal judge has thrown out a woman's suit claiming TRESemme shampoo caused her to suffer hair loss, saying evidence turned up in discovery shows she filed her claims nearly two years too late.

  • July 31, 2026

    Thermo Fisher Says Ex-VP Took 'Know-How' To Rival

    A former Thermo Fisher Scientific Inc. executive broke a noncompete agreement when she left for a position that will make her responsible for building a rival firm's sterile manufacturing business in direct competition with her old company, according to a case removed to North Carolina federal court Friday.

  • July 31, 2026

    End In Sight For Ovarian Cancer Patients With $5.5B+ J&J Deal

    The $5.5 billion global deal over talc ovarian cancer allows women to move past recent court setbacks requiring them to provide experts who can show a causal link between their disease and use of talc, and for defendant J&J to close a decade of litigation that included judicially criticized gambits to spin off liability through bankruptcy maneuvers.

  • July 31, 2026

    J&J's $25M Talc Appeal Can Advance, Conn. Panel Rules

    A Connecticut appeals court has advanced Johnson & Johnson's challenge to a $25 million talc trial judgment, denying a Massachusetts real estate developer's attempt to dismiss the appeal based on what he argued was a late-filed brief.

  • July 31, 2026

    AI Drugmaker Investors Seek Final OK For $9.75M Fraud Deal

    A class of investors in the artificial intelligence-driven drugmaker BioXcel Therapeutics Inc. has moved for final approval of a $9.75 million settlement to resolve claims that the stock price plunged after the company's late disclosure of compliance problems with a clinical trial for an Alzheimer's drug, and class counsel is seeking around 25%.

  • July 31, 2026

    No Standing For NY 'Aid-In-Dying' Law Challenge, Judge Rules

    A New York federal judge tossed a challenge by disability rights organizations and individuals to a state law enacted this year allowing patients with terminal illnesses to seek a doctor's assistance in ending their lives, finding the group lacked standing.

  • July 31, 2026

    Just For Men Maker Says Insurers Must Cover Injury Deals

    The maker of Just For Men hair color products said in a new federal complaint that its excess liability insurers improperly refused to cover personal injury lawsuit settlements connected to allegations that products from the popular line permanently discolored users' faces, after millions in the company's primary policies were exhausted.

  • July 31, 2026

    Insulet Urges Full Fed. Circ. To Revive $59M Trade Secret Win

    Insulin product developer Insulet Corp. has asked the full Federal Circuit to hear its arguments for reinstating a jury's $59.4 million trade secret theft verdict against EOFlow Co. Ltd., saying a split panel decision overturning the award reached a timeliness issue that was not mentioned by either party.

  • July 30, 2026

    9th Circ. Reverses Hologenix CEO's Tortious Interference Loss

    A Ninth Circuit panel reversed a $2.5 million judgment Thursday against Hologenix CEO Seth Casden by finding a district court erred in ruling the executive is not immune from a tortious interference claim while also reversing a Lanham Act disgorgement award totaling nearly $3 million.

  • July 30, 2026

    NC, Green Groups Call EPA-Chemours PFAS Deal Too Lenient

    North Carolina state leaders and environmental organizations asked the federal government to walk back a proposed settlement with Chemours over so-called forever chemical pollution from three factories, saying the deal amounted to a slap on the wrist.

  • July 30, 2026

    Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row

    Health plans and pharmacies backed by Cigna are asking the Second Circuit to revive a proposed class action alleging Bristol-Myers Squibb Co. and its Celgene subsidiary fraudulently obtained patents, filed sham lawsuits and paid off generic-drug makers to maintain a monopoly on the blockbuster blood cancer drug Pomalyst.

Expert Analysis

  • AG Watch: Oregon's Strategic Civil Enforcement Approach

    Author Photo

    Oregon Attorney General Dan Rayfield’s recent antitrust litigation activity and proposed staffing increase are the latest in a series of structural and policy changes that signal that the state Department of Justice is taking a more aggressive approach to civil enforcement, says Keturah Taylor at Cozen O'Connor.

  • How Nasdaq's 23/5 Rule Will Alter Public Offering Strategies

    Author Photo

    The U.S. Securities and Exchange Commission's recent approval of Nasdaq's proposal to extend trading hours to 23 hours a day, five days a week, may reshape how certain public offerings are executed, particularly for confidentially marketed public offerings, say attorneys at Faegre Drinker.

  • The Paradoxical Duty To Adopt AI When You Can't Bill For It

    Author Photo

    Both billing for hours saved using artificial intelligence and preserving billable time by not adopting AI may violate rules of professional conduct, but until bar associations' ethics rules catch up to this emerging economic dilemma, firms must decide how to adjust fee structures themselves, says Ines Lassalle at Peyrot & Associates.

  • Tips For Litigating Life Sciences Investigations At The ITC

    Author Photo

    The International Trade Commission may soon become a significant battleground for life sciences companies as global intellectual property and trade disputes continue, increasing the importance of learning the ITC's unique considerations and litigation strategies, say attorneys at Crowell & Moring.

  • Ch. 15 Ruling Is A Restructuring Blueprint For Cannabis Cos.

    Author Photo

    The recent Cannabist Chapter 15 recognition order is arguably the most significant cannabis bankruptcy development in U.S. history, providing a concrete and tested road map by which such companies with foreign parent structures can access the protective machinery of U.S. bankruptcy law, say attorneys at Saul Ewing.

  • Unsecured Synthetic Royalties May Be Returning

    Author Photo

    Recent royalty monetization deals mark a notable shift in a market that had largely moved away from unsecured synthetic royalty structures after a multiyear freeze triggered by the Mallinckrodt bankruptcy decision in 2022, which exposed a legal risk inherent to the structure, says Peter Schwartz at Covington.

  • Series

    Cow Horse Makes Me A Better Lawyer

    Author Photo

    Moving an unwilling 800-pound cow while riding a horse at high speed is exhilarating, a little unhinged and, at least for me, a surprisingly effective training ground for litigation — both demand focus, preparation over rigid planning and the willingness to act despite fear, says Ashley Zitrin at Glenn Agre.

  • Protecting AI-Driven Innovation In Life Sciences IP

    Author Photo

    Recent developments, including the U.S. Patent and Trademark Office's evolving inventorship standards, and the impact of artificial intelligence on the "person of ordinary skill in the art" standard demand that life sciences companies elevate AI patent strategy to a top priority, says Sandra Haberny at Quinn Emanuel.

  • What Prop 65 Listings For Welding Fumes, Drugs Mean For Cos.

    Author Photo

    With California poised to add welding chemicals and three medications to its list of known carcinogens under Proposition 65, businesses must assess risks from nontraditional pharmaceutical dispensing, occupational and environmental exposures to welding operations, and downstream exposures from the manufacture of both types of substances, says Gregory Berlin at Alston & Bird.

  • High Court's Hikma Decision Reshapes 'Skinny Label' Suits

    Author Photo

    The U.S. Supreme Court's decision in Hikma v. Amarin marks a significant victory for generic drug manufacturers, but rather than putting an end to so-called skinny label inducement claims, it narrows and refocuses them, say attorneys at Sterne Kessler.

  • Virginia's Cannabis Retail Veto Leaves Industry In Legal Limbo

    Author Photo

    Virginia Gov. Abigail Spanberger's recent veto of legislation that would have established a regulated retail cannabis framework halts momentum built by the General Assembly, but it also sends important signals about what a future regulatory framework must address to survive, says Charles Slemp at Cozen.

  • Checking For AI Errors Is Now A Two-Way Street

    Author Photo

    A handful of recent federal and state cases demonstrate the importance of checking for errors generated by artificial intelligence not only in your own court submissions, but also your opponent's, as well as when catching opposing counsel's AI mistakes could result in an award for attorney fees, says Tamara Barago at Hollingsworth.

  • Series

    The Biz Court Digest: Shoring Up Corporate Law In Maryland

    Author Photo

    Launched more than 20 years ago to improve complex corporate adjudication, Maryland's Business and Technology Case Management Program has been a solid success in some areas, but there always is room for improvement, says Bill Krulak at Miles & Stockbridge.

  • State Enviro Agencies Give Cosmetics Regulation A Makeover

    Author Photo

    As state oversight of cosmetics rapidly expands, the new statutes and regulations governing these products are being implemented by environmental agencies rather than consumer product regulators, requiring manufacturers, distributors and retailers to reevaluate their supply chains and procedures, say attorneys at Baker Botts.

  • FDA's Chemical Review Process Heats Up Food Industry Risk

    Author Photo

    The U.S. Food and Drug Administration's newly announced process for postmarket assessment of food additives signals a significant shift away from historically limited oversight, introducing both strategic opportunities and material risks for food manufacturers, ingredient suppliers and others in the food supply chain, say attorneys at Morgan Lewis.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.